Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04333654 · ClinicalTrials.gov registry record · Phase 1
Hydroxychloroquine in Outpatient Adults With COVID-19
A Phase 1 study, sponsored by Sanofi.
- Terminated
- Registry status
- Phase 1
- Development phase
- 8
- Enrollment target
NCT04333654 is a Phase 1 study that was terminated before completion, run by Sanofi. The registered enrollment target is 8 participants.
The verdict
NCT04333654, a Phase 1 study, was terminated before completion, sponsored by Sanofi.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 8 participants
- Enrollment target
Study Summary
Primary Objective: To assess the effect of hydroxychloroquine versus placebo on nasopharyngeal SARS-CoV-2 viral load in outpatient adults with COVID-19 Secondary Objectives: * To assess the effect of hydroxychloroquine versus placebo on clinical signs and symptoms and progression of disease in outpatient adults with COVID-19 * To assess the safety and tolerability of hydroxychloroquine in outpatient adults with COVID-19
Interventions
- DRUG Placebo
- DRUG Hydroxychloroquine SAR321068
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2020-04-12 |
| Est. Completion | 2020-05-26 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04333654
The ClinicalTrials.gov registry entry for NCT04333654 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sanofi, which has 713 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04333654 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04333654 about?
NCT04333654 is a clinical study titled "Hydroxychloroquine in Outpatient Adults With COVID-19". Primary Objective: To assess the effect of hydroxychloroquine versus placebo on nasopharyngeal SARS-CoV-2 viral load in outpatient adults with COVID-19 Secondary Objectives: * To assess the effect of hydroxychloroquine versus placebo on clinical signs and symptoms and progression of disease in ou...
What is the current status of trial NCT04333654?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 8 participants. The study started on 2020-04-12. Estimated completion is 2020-05-26.
What interventions are being tested in trial NCT04333654?
The interventions under investigation include: Placebo (DRUG), Hydroxychloroquine SAR321068 (DRUG).
Who is sponsoring clinical trial NCT04333654?
This trial is sponsored by Sanofi, which has 713 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.